Cell Genesys Announces Management Changes


Cell Genesys, Inc. announced that Dr. Robert J. Dow has joined the company in the newly created position of senior vice president, medical affairs. The company also announced that Matthew J. Pfeffer, vice president and chief financial officer, intends to resign to spend more time with his family and will remain in his position until a successor is appointed.

"We are delighted to have Rob join in our executive team given his broad pharmaceutical industry experience in product development and commercialization," stated Stephen A. Sherwin, M.D., chairman and chief executive officer. "We particularly look forward to Rob's leadership in further defining the global product approval and reimbursement strategy for our lead program, GVAX® prostate cancer vaccine, which entered Phase 3 development last year."

Dr. Dow, 54, who brings over 20 years of biopharmaceutical experience to Cell Genesys, was most recently chief executive officer of Biolitec Pharma Ltd., a U.K.-based biotechnology company, and also previously held senior executive positions with Quantanova and Scotia Holdings, plc. Prior to that, Dr. Dow was head of Global Drug Development with Hoffman-La Roche in Basel, Switzerland and previously was with Syntex Corporation for over 10 years in various senior positions in drug development. Dr. Dow holds a B.Sc. in Medical Science from the University of St. Andrews and his medical qualification, an MBChB degree, from the University of Dundee in Scotland. He also is a Fellow of the Royal College of Physicians of Edinburgh.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances